Analysts expect MeiraGTx Holdings PLC (NASDAQ:MGTX) to post earnings of ($0.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for MeiraGTx’s earnings. The company is expected to announce its next earnings report on Tuesday, June 25th.

On average, analysts expect that MeiraGTx will report full year earnings of ($3.50) per share for the current fiscal year, with EPS estimates ranging from ($3.97) to ($3.03). For the next year, analysts forecast that the business will post earnings of ($3.32) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for MeiraGTx.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.05.

MGTX has been the subject of a number of analyst reports. Zacks Investment Research raised MeiraGTx from a “sell” rating to a “hold” rating in a report on Tuesday, December 25th. Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of MeiraGTx in a research report on Thursday, January 31st. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $25.25.

In related news, major shareholder Life Sciences Maste Perceptive acquired 1,304,348 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were bought at an average price of $13.80 per share, for a total transaction of $18,000,002.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in MeiraGTx in the 4th quarter valued at $138,000. IFP Advisors Inc raised its position in MeiraGTx by 3,697.6% in the fourth quarter. IFP Advisors Inc now owns 75,192 shares of the company’s stock valued at $725,000 after purchasing an additional 73,212 shares during the last quarter. AE Wealth Management LLC bought a new position in MeiraGTx in the fourth quarter valued at about $1,031,000. Sphera Funds Management LTD. bought a new position in MeiraGTx in the fourth quarter valued at about $686,000. Finally, BlackRock Inc. bought a new position in shares of MeiraGTx during the third quarter worth about $1,968,000. 21.76% of the stock is currently owned by hedge funds and other institutional investors.

MGTX traded down $0.25 during trading on Tuesday, reaching $18.50. 87,148 shares of the company’s stock were exchanged, compared to its average volume of 111,847. MeiraGTx has a fifty-two week low of $7.98 and a fifty-two week high of $21.93. The company has a market capitalization of $613.90 million and a P/E ratio of -4.21.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.

Further Reading: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on MeiraGTx (MGTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with's FREE daily email newsletter.